Skip to main content


Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure

Fig. 1

Comparison of the treatment effects of SGLT2 inhibitors on CV death and hospitalization for HF, stratified according to the presence or absence of history of HF at baseline. In the EMPA-REG OUTCOME trial, both outcomes were significantly decreased in the subgroups without HF at baseline, while in the CANVAS Program, the outcomes were reduced in the subgroups with HF at baseline, although there was no statistically significant treatment effect across the subgroups. CV cardiovascular, HF heart failure, SGLT2 sodium glucose co-transporter 2

Back to article page